People
Isabel Jiménez Bernal
Isabel Jiménez Bernal is an investment professional at Asabys Partners, publicly promoted to Principal in2025. Augustine Therapeutics’ June2024 first SeriesA closing announcement named Isabel Jiménez of Asabys as a new board observer. Her full Asabys identity is corroborated by her own public promotion post and existing institutional affiliation; she is distinct from Isabel Jiménez at Biocross. The Augustine observer relationship is a dated appointment and does not establish a personal investment or current executive employment. Asabys’ current published biography confirms she is a Principal who joined in 2022, and currently serves as board observer at Augustine Therapeutics and Orikine Bio. She previously worked with Ysios Capital and in hemato-oncology and immunology at VHIO; she holds a medicine PhD from the Autonomous University of Barcelona, an immunology master’s and an ESADE Executive MBA.
Roles
Principal
Board Observer (current Asabys biography; appointed June2024)